Patents by Inventor Justyna E. Wolak-Dinsmore
Justyna E. Wolak-Dinsmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240125719Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosample may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: ApplicationFiled: September 21, 2023Publication date: April 18, 2024Applicant: Liposcience, Inc.Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
-
Publication number: 20240096497Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: ApplicationFiled: June 16, 2023Publication date: March 21, 2024Applicant: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
-
Publication number: 20240077439Abstract: Methods and systems for detecting a presence and a concentration of biomarkers relevant to kidney stone formation may be useful in determining a personalized therapeutic approach for a subject. Nuclear Magnetic Resonance (NMR) spectroscopy may be a valuable tool in detecting various biomarkers related to various disease states. A biosample obtained from a subject may be examined using NMR spectroscopy to determine the presence and the concentration of relevant biomarkers.Type: ApplicationFiled: August 31, 2023Publication date: March 7, 2024Inventors: Steven P. Matyus, Erwin Garcia, Justyna E. Wolak-Dinsmore
-
Patent number: 11782002Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: GrantFiled: March 9, 2020Date of Patent: October 10, 2023Assignee: LipoScience, Inc.Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
-
Patent number: 11710568Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: GrantFiled: July 2, 2019Date of Patent: July 25, 2023Assignee: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
-
Patent number: 11692995Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.Type: GrantFiled: November 13, 2020Date of Patent: July 4, 2023Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
-
Publication number: 20210080452Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.Type: ApplicationFiled: November 13, 2020Publication date: March 18, 2021Applicant: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
-
Patent number: 10852293Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.Type: GrantFiled: September 14, 2016Date of Patent: December 1, 2020Assignee: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
-
Publication number: 20200355634Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: ApplicationFiled: March 9, 2020Publication date: November 12, 2020Applicant: Liposcience, Inc.Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
-
Patent number: 10613044Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: GrantFiled: November 30, 2016Date of Patent: April 7, 2020Assignee: Liposcience, Inc.Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
-
Publication number: 20200005943Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: ApplicationFiled: July 2, 2019Publication date: January 2, 2020Applicant: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
-
Patent number: 10388414Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: GrantFiled: May 3, 2016Date of Patent: August 20, 2019Assignee: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
-
Patent number: 9792410Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: GrantFiled: June 7, 2013Date of Patent: October 17, 2017Assignee: LipoScience, Inc.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
-
Publication number: 20170184521Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: ApplicationFiled: November 30, 2016Publication date: June 29, 2017Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
-
Patent number: 9541620Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: GrantFiled: May 16, 2013Date of Patent: January 10, 2017Assignee: LIPOSCIENCE, INC.Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
-
Publication number: 20170003269Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states . The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.Type: ApplicationFiled: September 14, 2016Publication date: January 5, 2017Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
-
Patent number: 9535144Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.Type: GrantFiled: March 13, 2013Date of Patent: January 3, 2017Assignee: LIPOSCIENCE, INC.Inventors: James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Stanley L. Hazan
-
Publication number: 20160321424Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: ApplicationFiled: May 3, 2016Publication date: November 3, 2016Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
-
Patent number: 9470771Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.Type: GrantFiled: March 14, 2013Date of Patent: October 18, 2016Assignee: LIPOSCIENCE, INC.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
-
Patent number: 9361429Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.Type: GrantFiled: March 14, 2013Date of Patent: June 7, 2016Assignee: LIPOSCIENCE, INC.Inventors: James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier